The sticking point for Sanofi could be Insmed's sky-high valuation, with the report suggesting the pharma group would have to ...
Alongside the CEO appointment, Gianluca Fuggetta joined as chief financial officer. Prior to joining Sibylla, Fuggetta served ...
Prostate Progress, a UK research programme led by Prostate Cancer Research (PCR) in partnership with the NHS, is expanding ...
Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that can drive the prediction, design, and discovery of new therapies. The ...
Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the ...
Rasonque has been applauded as a major step forward in the treatment of pancreatic cancer, a notoriously aggressive and ...
Sanofi is already a big player in Gaucher disease, selling the ERT Cerezyme (imiglucerase) for all three types, as well as ...
Livsayis (cemdisiran) has been approved by the FDA for adults with AChR antibody-positive gMG, the most common form of the ...
Donald Trump nominated Overton – a White House aide, physician, and vocal opponent of abortion – in the summer. The following ...
MSD joins Johnson & Johnson, Novartis, and Eli Lilly among London-based Isomorphic's publicly announced R&D partners. While ...
Diabetes drug development has changed more in the last 10 years than in the previous three decades combined. Indeed, today, ...
MSD has called a halt to three trials of BTK inhibitor nemtabrutinib – added to its pipeline through its $2.7 billion ...